OCUL Ocular Therapeutix Inc.

3.44
-0.03  -1%
Previous Close 3.47
Open 3.44
Price To Book 19.11
Market Cap 162,355,004
Shares 47,196,222
Volume 190,706
Short Ratio
Av. Daily Volume 489,324
Stock charts supplied by TradingView

NewsSee all news

  1. Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the

  2. Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  3. Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval June 21, 2019.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial initiation announced September 24, 2019. Top-line data due 1H 2020.
DEXTENZA
Allergic conjunctivitis
Phase 3 data May 20, 2019 did not meet primary endpoint.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease
Phase 1 initial data released April and May 2019.
OTX-TIC
Glaucoma and ocular hypertension
Phase 1 dosing of first patient announced February 20, 2019.
OTX-TKI
Wet Age-related Macular Degeneration (AMD)

Latest News

  1. Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the

  2. Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  3. Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that